| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
Cinitapride is a gastroprokinetic agent and antiulcer agent of the benzamide class which is marketed in Spain and Mexico. It acts as an agonist of the 5-HT1 and 5-HT4 receptors and as an antagonist of the 5-HT2 receptors. |
| Indication |
For the treatment of gastrointestinal disorders associated with motility disturbances such as gastroesophageal reflux disease, non-ulcer dyspepsia and delayed gastric emptying. |
| Toxicity |
The symptoms of overdose include drowsiness, confusion and extrapyramidal effects. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Absorption |
The absorption of cinitapride (12mg) following oral administration was rapid, with peak levels being achieved 2 h after dosing; absorption following intramuscular administration (4mg) was even more rapid, with peak levels (50% more that oral levels) being achieved 1 h after dosing. |
| Half Life |
3-5 h during the first 8 h and a residual half-life greater than 15 h thereafter. |
| References |
| • |
Alarcon-de-la-Lastra Romero C, Lopez A, Martin MJ, la Casa C, Motilva V: Cinitapride protects against ethanol-induced gastric mucosal injury in rats: role of 5-hydroxytryptamine, prostaglandins and sulfhydryl compounds. Pharmacology. 1997 Apr;54(4):193-202.
[Pubmed]
|
|
| External Links |
|